Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia
Status:
Completed
Trial end date:
2017-02-06
Target enrollment:
Participant gender:
Summary
Randomized, double-blind clinical trial of tocilizumab vs. placebo as add-on treatment for
residual positive, negative, and cognitive symptoms in schizophrenia. The primary study
hypothesis is that individuals receiving tocilizumab will show greater improvements in their
PANSS total scores than those taking placebo.